Rineterkib
Modify Date: 2025-08-20 15:47:00
Rineterkib structure
|
Common Name | Rineterkib | ||
|---|---|---|---|---|
| CAS Number | 1715025-32-3 | Molecular Weight | 578.42 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H27BrF3N5O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of RineterkibERK-IN-1 (compound B) is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC (non-small celllung cancer), BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovanan cancer[1]. |
| Name | ERK-IN-1 |
|---|
| Description | ERK-IN-1 (compound B) is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC (non-small celllung cancer), BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovanan cancer[1]. |
|---|---|
| Related Catalog | |
| Target |
RAF ERK1 ERK2 |
| In Vivo | ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice[1]. Animal Model: Calu-6 NSCLC xenograft tumor models in mice[1]. Dosage: 50, 75 mg/kg. Administration: Orally either daily (qd) or every other day (q2d) for 27 days. Result: Significantly reduced the tumor volume. |
| References |
[1]. WO2018051306A1. |
| Molecular Formula | C26H27BrF3N5O2 |
|---|---|
| Molecular Weight | 578.42 |
| InChIKey | YFCIFWOJYYFDQP-PTWZRHHISA-N |
| SMILES | CNCC(NC(=O)c1ccc(-c2nc(C3CCC(O)C(F)C3)cnc2N)cc1F)c1cc(F)cc(Br)c1 |
| Storage condition | -20°C |